



LABioMed
Los Angeles
Biomedical
Research Institute
at Harbor-UCLA Medical Center

CLINICAL TRIAL

NAME OF STUDY: TARGET: Trials Assessing Ranirestat Global Evaluation of Treatment

A 2 Year, Randomized, double-blind, Placebo Controlled, Multi-center Phase II-III Study to Evaluate the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy

TYPE OF VOLUNTEERS BEING SOUGHT:

- Type 1 or Type 2, Insulin dependent or non insulin dependent
- Best possible glucose control for at least 3 months before screening
- Male or Female, Ages 18 to 75
- History of Diabetic Peripheral Neuropathy (numbness, pain, tingling) in both feet or hands
- No history of Cancer within 5 years
- No current major depressive disorder, bipolar disorder or past history of suicide attempt

PURPOSE OF STUDY:

To determine if 40 mg and 80 mg Ranirestat is effective to improve nerve conduction testing, signs and symptoms as well as health-related quality of life, pain and complications compared to placebo in subject with mild to moderate diabetic sensorimotor polyneuropathy

DETAILS OF STUDY:

The study will last about 26 months...Subjects who complete the study will be eligible to enter a double-blind extension study in which they will be re-randomized to Ranirestat or placebo for up to 3 years

STUDY START DATE: July 2009

STUDY END DATE: September 30 2010

CONTACT INFORMATION (PHONE, EMAIL, WEBSITE):

Colleen Cortez RN, CDE
310-222-1870 office, 310-501-1284 Pager
ccortez@labiomed.org

For more information, please visit <http://www.labiomed.org/clinicaltrials/ctmain.htm>



LABioMed IRB NUMBER: 13752-01

IRB APPROVAL DATE: 5/10/2010